POSTER SESSION III
Tuesday, March 20, 2012 — 9:30 AM - 12:00 Noon
CC Exhibit Hall B3 & C
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
LIVER PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
242
BRUCE: A Novel Protein Associated with Carcinogenesis of Liver and Potential Marker for Differential Diagnosis
(1759)
R Patel, J Lu, C Du, J Wang - University of Cincinnati College of Medicine, Cincinnati, OH
The Effect of the Etiology of Cirrhosis on Glypican-3 Expression in Hepatocellular Carcinoma
(1756)
JM Orrock, T Mounajjed, L Zhang, T-T Wu - Mayo Clinic, Rochester, MN
CD10 (MME) Upregulation Is Commonly Associated with Hepatocellular Carcinoma Related to Hepatitis C Virus Infection and Chemoembolization
(1744)
L Lee, U Sarpel, M Ligr, C Hajdu, M Cho, MX Kong, Q Ren, P Lee, R Xu - New York University School of Medicine, New York
Immunohistochemical Analysis of Six1 in Hepatocellular Carcinoma: Correlation with Proliferation, Prognostic Parameters, and Outcome
(1771)
J Wang, D Lawson, C Cohen - Emory University, Atlanta
The Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated with Non-Alcoholic Steatohepatitis
(1719)
JF Busler, SK Geevarghese, BS Kelly, MK Washington - Vanderbilt University Medical Center, Nashville, TN
Oncogenic SULF2 Protein Expression Is Associated with Pathogenesis of Cirrhosis and Hepatobiliary Carcinoma
(1742)
J-P Lai, PP Aung, Z Wang, A Rosenberg, D Kleiner, LR Roberts, M Miettinen - National Cancer Institute, National Institutes of Health, Bethesda, MD; Mayo Clinic, Rochester, MN
Bile Salt Export Pump (BSEP): A Sensitive and Specific Marker of Hepatocytic Differentiation in Liver Tumors
(1741)
SM Lagana, H Remotti, RK Moreira - Columbia University Medical Center, New York, NY
Comparison of Hepatocellular Markers for Diagnosis of Poorly- Differentiated Hepatocellular Carcinoma: High Sensitivity with Combined Use of Arginase-1 and Glypican-3
(1760)
DGK Phillips, D Jain, M Torbenson, T-T Wu, MMC Yeh, S Kakar - University of California, San Francisco, San Francisco, CA; Yale-New Haven Hospital, New Haven, CT; The Johns Hopkins Hospital, Baltimore, MD; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA
Utility of HSP70, Glutamine Synthethase and Glypican-3 in Distinguishing Hepatocellular Adenoma from Well- Differentiated Hepatocellular Carcinoma
(1753)
TB Nguyen, S Kakar - University of California, San Francisco, CA
Hepatocellular Carcinomas Arising in Adenomas: Similar Immunohistochemical and Cytogenetic Features in Adenoma and Hepatocellular Carcinoma Portions of the Tumor
(1735)
S Kakar, JP Grenert, V Paradis, N Pote, S Jakate, L Ferrell - UCSF, San Francisco; Rush University, Chicago; Beaujon Hospital, Clichy, France
Type II Ground Glass Hepatocytes Are Strongly Associated with Fibrosis Stage and Hepatocellular Carcinoma
(1740)
F-Y Kuo, J Alexander, M Torbenson, M Yeh - Chang Gung Medical Center, Kaohsiung, Taiwan; Univ of Washington, Seattle; Johns Hopkins Univ, Baltimore
Subjective Pathologic Estimates of Viable Tumor in Ablated Hepatocellular Carcinomas (HCC) Are Adequate for Routine Practice and for Radiology/Pathology Correlation Studies
(1729)
JA Hanson, A VanDyke, J Gibson, M Robert, D Jain, KA Mitchell - Yale New Haven Hospital, New Haven, CT
Immunophenotypic Subtypes of Hepatic Adenomas in a Large Tertiary Care Center in the United States
(1750)
E McMillen, S Lagana, F Bao - Columbia University Medical Center, New York, NY
button next to any title to add to Itinerary Planner...
Add
